Kailera Therapeutics, Inc.
NASDAQ:KLRABiotechnology
+$0.51 today
- Market cap
- $1.53B
- Beta
- 0.00
Volume 0.42M
Average 0.80M
Returns on capital
Kailera Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
41.8%
avg 41.8%
ROIC
-24.5%
avg -24.5%
ROA
-21.5%
avg -21.5%
Analysis
ROE is currently the strongest return metric at 41.8% versus its period average of 41.8%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Jamie Beth Coleman | Chief Commercial Officer | USD 911.28K | 48 | 75.00K | 0.06% |
Ronald C. Renaud Jr. | President, CEO & Director | USD 863.87K | 57 | 38.09K | 0.03% |
Paul Douglas Burgess | Chief Operating & Business Officer | USD 670.19K | 52 | — | — |
Kathleen Tregoning | Chief Corporate Affairs Officer | — | 55 | 175.00K | 0.14% |
Corey Manchester | Treasurer | — | — | — | — |
Scott Wasserman | Chief Medical Officer | — | 56 | — | — |
Maura Gavaghan | Vice President of Corporate Communications & Investor Relations | — | — | — | — |
Scott Akamine | Chief Legal Officer & Secretary | — | 41 | 60.00K | 0.05% |
Paula A. Cloghessy SHRM-SCP SPHR | Chief People Officer | — | 54 | — | — |
Douglas W. Pagan | Chief Financial Officer | — | 54 | 100.00K | 0.08% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 6, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$326.75M
Sells
0
$0.00
Net Transaction Value
+$326.75M
Net buying
Most Active
BAIN CAPITAL INVESTORS LLC
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Apr 20, 26Apr 20, 2026 | BAIN CAPITAL INVESTORS LLC Indirect | Buy | $134.4M$134,375,008.00 |
| Apr 20, 26Apr 20, 2026 | Koppel Adam Indirect | Buy | $25M$25,000,000.00 |
| Apr 20, 26Apr 20, 2026 | Bain Capital Life Sciences Investors, LLC Indirect | Buy | $25M$25,000,000.00 |
| Apr 20, 26Apr 20, 2026 | Kaplan Andrew T. Indirect | Buy | $134.4M$134,375,008.00 |
| Apr 20, 26Apr 20, 2026 | RTW INVESTMENTS, LP Indirect | Buy | $8M$8,000,000.00 |
Summary
Insiders reported 5 buys worth $326.75M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $326.75M. BAIN CAPITAL INVESTORS LLC was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Kailera Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about KLRA's management, answered from reported figures.
Who manages KLRA?
Kailera Therapeutics, Inc. (KLRA) lists 10 active executives. The top listed executive is Kathleen Tregoning, Chief Corporate Affairs Officer.
Are KLRA insiders buying or selling?
Recent insider activity shows net buying of $350.79M.
Continue the stock analysis
Jump to another research area for this company.